Roche's willingness to continue plugging away with Alzheimer's programs despite setbacks has moved AC Immune a step closer to filing for an IPO. The Big Pharma has decided to advance the Alzheimer's treatment it licensed from AC Immune into Phase III, giving its partner the confidence to consider tapping public markets for cash.
Roche is terminating its collaboration with Molecular Partners, nixing an oncology partnership worth up to $1 billion as it reshuffles its pipeline.
India has denied an appeal by Roche on a patent claim for eye infection treatment Valcyte for AIDS patients, the Economic Times reports.
With biosimilar competition beginning to appear on the market horizon, Roche believes it has a shot at pushing its late-stage pipeline drugs to the market in time to stay ahead of the threat to its bottom line. And its PD-L1 cancer drug star atezolizumab is once again being pushed onto center stage as Roche appears determined to place most of its bets on its in-house pipeline.
Roche isn't in denial about oncoming biosimilar competition for its top-selling cancer drugs. But CEO Severin Schwan says its new meds are on track to fill in the gap--and sales growth in the first half of the year go some way toward proving that case.
Roche is resuscitating development for gantenerumab, an Alzheimer's treatment that flamed out in Phase III late last year, as recent clinical results have emboldened the company to launch new studies.
Social media success in consumer marketing has advanced beyond counting fans and followers. Today it's all about shares, retweets and links that indicate real consumer engagement with brands....
AC Immune has picked up a milestone payment in its CHF 400 million ($421 million) anti-tau collaboration with Genentech. The Roche subsidiary handed over the cash after selecting a tau-targeting antibody developed in the collaboration to advance toward the clinic.
Merck's Keytruda and Bristol-Myers' Opdivo may have the next-gen cancer immunotherapy market to themselves for now. But Roche is in catch-up mode, and some new data add to its case for a sooner-rather-than-later regulatory approval.
Roche says its closely watched PD-L1 checkpoint inhibitor atezolizumab (MPDL3280A) hit its primary endpoint in a midstage study for bladder cancer, shrinking tumors for a narrowly defined set of patients and setting the stage for early discussions with the FDA about the possibility of an accelerated approval for this "breakthrough" drug.